Large-cap Health Care company Moderna has logged a -1.8% change today on a trading volume of 514,472. The average volume for the stock is 3,381,447.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Based in Cambridge, United States the company has 3,900 full time employees and a market cap of $48,261,058,560.
The company is now trading -41.57% away from its average analyst target price of $216.67 per share. The 15 analysts following the stock have set target prices ranging from $93.0 to $430.0, and on average give Moderna a rating of buy.
Over the last year, MRNA shares have gone down by -11.3%, which represents a difference of -14.0% when compared to the S&P 500. The stock's 52 week high is $217.25 per share and its 52 week low is $115.03. Based on Moderna's compound average operating margin growth of 1.1% over the last 4 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 19,263,000 | 4,427,000 | 48.9 | -34.77 |
| 2021-12-31 | 17,736,000 | 1,823,000 | 74.97 | 126.97 |
| 2020-12-31 | 274,490 | 1,029,701 | -278.02 | 75.53 |
| 2019-12-31 | 48,036 | 593,756 | -1136.06 | n/a |
